eMedicine Specialties > Dermatology > Malignant Neoplasms

Basal Cell Carcinoma

Author: Michael L Ramsey, MD, Director, Mohs Surgery Fellowship, Co-Director, Procedural Dermatology Fellowship, Department of Dermatology, Geisinger Medical Center
Coauthor(s): Lindsay Dane Sewell, MD, Staff Physician, Department of Dermatology, Geisinger Medical Center
Contributor Information and Disclosures

Updated: Sep 11, 2009

Introduction

Background

Basal cell carcinoma (BCC) is the most common malignancy in humans. It typically occurs in areas of chronic sun exposure. BCC is usually slow growing and rarely metastasizes, but it can cause clinically significant local destruction and disfigurement if neglected or inadequately treated. Prognosis is excellent with proper therapy.

Pathophysiology

Many believe that basal cell carcinomas (BCCs) arise from pluripotential cells in the basal layer of the epidermis or follicular structures. These cells form continuously during life and can form hair, sebaceous glands, and apocrine glands. Tumors usually arise from the epidermis and occasionally arise from the outer root sheath of a hair follicle, specifically from hair follicle stem cells residing just below the sebaceous gland duct in an area called the bulge.

The patched/hedgehog intracellular signaling pathway plays a role in both sporadic BCCs and in nevoid BCC syndrome (Gorlin syndrome). This pathway influences differentiation of a variety of tissues during fetal development. After embryogenesis, it continues to function in regulation of cell growth and differentiation. Loss of inhibition of this pathway is associated with human malignancy, including BCC.

The hedgehog gene encodes an extracellular protein that binds to a cell membrane receptor complex to start a cascade of cellular events leading to cell proliferation. Of the 3 known human homologs, Sonic hedgehog (SHH) protein is the most relevant to BCC. Patched (PTCH) is a protein that is the ligand-binding component of the hedgehog receptor complex in the cell membrane. The other protein member of the receptor complex, smoothened (SMO), is responsible for transducing hedgehog signaling to downstream genes.1,2

When SHH is present, it binds to PTCH, which then releases and activates SMO. SMO signaling is transduced to the nucleus via Gli. When SHH is absent, PTCH binds to and inhibits SMO. Mutations in the PTCH gene prevent it from binding to SMO, simulating the presence of SHH . The unbound SMO and downstream Gli are constitutively activated, thereby allowing hedgehog signaling to proceed unimpeded. The same pathway may also be activated via mutations in the SMO gene, which also allows unregulated signaling of tumor growth. How these defects cause tumorigenesis is not fully understood, but most BCCs have abnormalities in either PTCH or SMO genes. Some even consider defects in the hedgehog pathway to be requirements for BCC development.

UV-induced mutations in the TP53 tumor suppressor gene, which resides on band 17p13.1, have been found in some cases of BCC.3 Activated BCL2 (an antiapoptosis proto-oncogene) also is commonly found in BCCs and may be detected immunohistochemically.

Frequency

United States

The annual incidence of basal cell carcinoma (BCC) is approximately 900,000 cases (550,000 in men, 350,000 in women). The age-adjusted incidence per 100,000 white individuals is 475 cases in men and 250 cases in women. The estimated lifetime risk of BCC in the white population is 33-39% in men and 23-28% in women.

Mortality/Morbidity

Basal cell carcinoma (BCC) can cause clinically significant morbidity if allowed to progress. Because this cancer most commonly affects the head and neck, cosmetic disfigurement is not uncommon. Loss of vision or the eye may occur with orbital involvement. Perineural spread can result in loss of nerve function and in deep and extensive invasion of the tumor. These neoplasms are often friable and prone to ulceration; thus, they provide a nidus for infection. Death from BCC is extremely rare.

Race

Basal cell carcinoma (BCC) is generally a disorder of white individuals, especially those with fair skin. It is rare in dark-skinned individuals.

Sex

The male-to-female ratio for basal cell carcinoma (BCC) is approximately 3:2.

Age

Basal cell carcinoma (BCC) most commonly occurs in adulthood, especially in elderly persons.

Clinical

History

Basal cell carcinoma (BCC) patients often present with a nonhealing sore of varying duration. The lesions are typically seen on the face, ears, scalp, neck, or upper trunk. Mild trauma, such as face washing or drying with a towel, initially may cause bleeding. A history of chronic recreational or occupational sun exposure is commonly elicited. Intense sun exposure often occurred in childhood or young adulthood.

Physical

Several clinical and histologic subtypes of basal cell carcinoma (BCC) may exhibit different patterns of behavior. Recognizing the various types is important because aggressive therapy is often necessary for variants such as micronodular, infiltrating, or morpheaform BCC. When one examines possible skin cancers, the best plan is to use good lighting and magnification. The affected skin should be stretched, squeezed, and palpated to best estimate the size and depth of the tumor. Oblique illumination of the tumor can highlight surface changes, such as a rolled border.

  • Nodular BCC: This is the most common variety of BCC. Nodular BCCs most commonly occur on the head, neck, and upper back. They may have some of the following features:
    • Waxy papules with central depression (see image below)
    • Pearly appearance
    • Erosion or ulceration
    • Bleeding
    • Crusting
    • Rolled (raised) border (see images below)
    • Translucency
    • Telangiectases over the surface
    • History of bleeding with minor trauma

    • Nodular basal cell carcinoma appearing as a waxy,...

      Nodular basal cell carcinoma appearing as a waxy, translucent papule with central depression and a few small erosions.

      [ CLOSE WINDOW ]
      Nodular basal cell carcinoma appearing as a waxy,...

      Nodular basal cell carcinoma appearing as a waxy, translucent papule with central depression and a few small erosions.


    • Scale, erythema, and a threadlike raised border a...

      Scale, erythema, and a threadlike raised border are present in this superficial basal cell carcinoma on the trunk.

      [ CLOSE WINDOW ]
      Scale, erythema, and a threadlike raised border a...

      Scale, erythema, and a threadlike raised border are present in this superficial basal cell carcinoma on the trunk.


    • Large, superficial basal cell carcinoma.

      Large, superficial basal cell carcinoma.

      [ CLOSE WINDOW ]
      Large, superficial basal cell carcinoma.

      Large, superficial basal cell carcinoma.

  • Pigmented BCC: In addition to features seen in lesions of nodular BCC, lesions of pigmented BCC contain increased brown or black pigment and are most common in individuals with dark skin (see image below).

  • Pigmented basal cell carcinoma has features of no...

    Pigmented basal cell carcinoma has features of nodular basal cell carcinoma with the addition of dark pigmentation from melanin deposition. The pigmentation often has the appearance of dark droplets in the lesion, as shown here.

    [ CLOSE WINDOW ]
    Pigmented basal cell carcinoma has features of no...

    Pigmented basal cell carcinoma has features of nodular basal cell carcinoma with the addition of dark pigmentation from melanin deposition. The pigmentation often has the appearance of dark droplets in the lesion, as shown here.

  • Cystic BCC: Lesions of cystic BCC are translucent blue-gray cystic nodules that may mimic benign cystic lesions.
  • Superficial BCC: This variety appears as scaly patches or papules that are pink to red-brown, often with central clearing. A threadlike border is common. Erosion is less common in superficial BCC than in nodular BCC (see image below). Superficial BCC is common on the trunk and has little tendency to become invasive. The papules may mimic psoriasis or eczema, but they are slowly progressive and not prone to fluctuate in appearance. Numerous superficial BCCs may indicate arsenic exposure.

  • This translucent pink papule has telangiectases a...

    This translucent pink papule has telangiectases and a crusted erosion, characteristic of nodular basal cell carcinoma.

    [ CLOSE WINDOW ]
    This translucent pink papule has telangiectases a...

    This translucent pink papule has telangiectases and a crusted erosion, characteristic of nodular basal cell carcinoma.

  • Micronodular BCC: This aggressive BCC subtype has the typical BCC distribution. It is not prone to ulceration, it may appear yellow-white when stretched, and it is firm to the touch. It may have a seemingly well-defined border.
  • Morpheaform and infiltrating BCC: These are aggressive BCC subtypes with sclerotic (scarlike) plaques or papules. The border is usually ill defined and often extends well beyond clinical margins. Ulceration, bleeding, and crusting are uncommon. It may be mistaken for scar tissue (see images below).

  • This infiltrating basal cell cancer has ill-defin...

    This infiltrating basal cell cancer has ill-defined borders and telangiectases.

    [ CLOSE WINDOW ]
    This infiltrating basal cell cancer has ill-defin...

    This infiltrating basal cell cancer has ill-defined borders and telangiectases.


  • Large, scarlike morpheaform basal cell cancer.

    Large, scarlike morpheaform basal cell cancer.

    [ CLOSE WINDOW ]
    Large, scarlike morpheaform basal cell cancer.

    Large, scarlike morpheaform basal cell cancer.

Younger patients (<40 y) may have a lower prevalence of BCC on the head and neck and a higher prevalence on the trunk, with greater tendency to superficial BCC, than in older patients.4 Childhood BCC is exceedingly rare in the absence of other underlying conditions. Only 107 cases of de novo childhood BCC have been reported in the literature, but the majority (90%) occurred on the head and neck, and aggressive subtypes were observed in 20% of the total cases.5

Causes

  • UV radiation: This is the most important and common cause of basal cell carcinoma (BCC). Short-wavelength UV radiation (290-320 nm, sunburn rays) is believed to play a greater role in BCC formation than long-wavelength UVA radiation (320-400 nm, tanning rays). In addition, chronic sun exposure appears to be important in the development of BCC. A latency period of 20-50 years is typical between the time of UV damage and the clinical onset of BCC.
  • Other radiation: X-ray and grenz-ray exposure are associated with BCC formation.
  • Arsenic exposure: Chronic exposure to arsenic is associated with BCC development. Exposure may be medicinal, occupational, or dietary. A contaminated water supply is most commonly implicated.
  • Immunosuppression: Immunosuppression is associated with a modest increase in the risk of BCC.
  • Xeroderma pigmentosum: This autosomal recessive disease predisposes people to rapid aging of exposed skin, starting with pigmentary changes and progressing to BCC, squamous cell carcinoma, and malignant melanoma. The effects are due to an inability to repair UV-induced DNA damage. Other features include corneal opacities, eventual blindness, and neurologic deficits.
  • Nevoid BCC syndrome (basal cell nevus syndrome, Gorlin syndrome): Multiple BCCs occur in this autosomal dominant condition, often starting at an early age. Odontogenic keratocysts, palmoplantar pitting, intracranial calcification, and rib anomalies may be seen. Various tumors, such as medulloblastomas, meningioma, fetal rhabdomyoma, and ameloblastoma, can also occur. Mutations in the hedgehog signaling pathway, particularly the PTCH gene, are causative.6
  • Bazex syndrome (Bazex-Dupre-Christol syndrome): This is an x-linked dominant condition with features of follicular atrophoderma (ice-pick marks, especially on dorsum of the hands), multiple BCCs, local anhidrosis (decreased or absent sweating), and congenital hypotrichosis.7
  • Rombo syndrome8 : This is an autosomal dominant condition distinguished by BCC and atrophoderma vermiculatum, trichoepitheliomas, hypotrichosis milia, and peripheral vasodilation with cyanosis.
  • History of nonmelanoma skin cancer (BCC or squamous cell carcinoma): Persons with one nonmelanoma skin cancer are at increased risk of developing others in the future. The rate of new nonmelanoma skin cancer is 35% at 3 years and 50% at 5 years after an initial diagnosis of skin cancer.9

More on Basal Cell Carcinoma

Overview: Basal Cell Carcinoma
Differential Diagnoses & Workup: Basal Cell Carcinoma
Treatment & Medication: Basal Cell Carcinoma
Follow-up: Basal Cell Carcinoma
Multimedia: Basal Cell Carcinoma
References
[ CLOSE WINDOW ]

References

  1. Bale AE, Yu KP. The hedgehog pathway and basal cell carcinomas. Hum Mol Genet. Apr 2001;10(7):757-62. [Medline].

  2. Wicking C, McGlinn E. The role of hedgehog signalling in tumorigenesis. Cancer Lett. Nov 8 2001;173(1):1-7. [Medline].

  3. National Center for Biotechnical Information. Tumor Protein p53; TP53. Online Mendelian Inheritance in Man. Available at http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=191170. Accessed November 7, 2007.

  4. Betti R, Radaelli G, Mussino F, Menni S, Crosti C. Anatomic location and histopathologic subtype of basal cell carcinomas in adults younger than 40 or 90 and older: any difference?. Dermatol Surg. Feb 2009;35(2):201-6. [Medline].

  5. Griffin JR, Cohen PR, Tschen JA, et al. Basal cell carcinoma in childhood: case report and literature review. J Am Acad Dermatol. Nov 2007;57(5 Suppl):S97-102. [Medline].

  6. Klein RD, Dykas DJ, Bale AE. Clinical testing for the nevoid basal cell carcinoma syndrome in a DNA diagnostic laboratory. Genet Med. Nov-Dec 2005;7(9):611-9. [Medline].

  7. National Center for Biotechnical Information. Bazex Syndrome; BZX. Online Mendelian Inheritance in Man. Available at http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=301845. Accessed November 7, 2007.

  8. Michaëlsson G, Olsson E, Westermark P. The Rombo syndrome: a familial disorder with vermiculate atrophoderma, milia, hypotrichosis, trichoepitheliomas, basal cell carcinomas and peripheral vasodilation with cyanosis. Acta Derm Venereol. 1981;61(6):497-503. [Medline].

  9. Karagas MR. Occurrence of cutaneous basal cell and squamous cell malignancies among those with a prior history of skin cancer. The Skin Cancer Prevention Study Group. J Invest Dermatol. Jun 1994;102(6):10S-13S. [Medline].

  10. [Guideline] U.S. Preventive Services Task Force. Screening for skin cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. Feb 3 2009;150(3):188-93. [Medline].

  11. [Guideline] From L, Marrett L, Rosen C, et al. Screening for skin cancer: a clinical practice guideline. National Guidelines Clearinghouse. Jun 2007.

  12. [Guideline] Telfer NR, Colver GB, Morton CA. Guidelines for the management of basal cell carcinoma. Br J Dermatol. Jul 2008;159(1):35-48. [Medline].

  13. Silverman MK, Kopf AW, Grin CM, Bart RS, Levenstein MJ. Recurrence rates of treated basal cell carcinomas. Part 2: Curettage-electrodesiccation. J Dermatol Surg Oncol. Sep 1991;17(9):720-6. [Medline].

  14. Silverman MK, Kopf AW, Bart RS, Grin CM, Levenstein MS. Recurrence rates of treated basal cell carcinomas. Part 3: Surgical excision. J Dermatol Surg Oncol. Jun 1992;18(6):471-6. [Medline].

  15. Bennett RG. Current concepts in Mohs micrographic surgery. Dermatol Clin. Oct 1991;9(4):777-88. [Medline].

  16. Roenigk RK. Mohs' micrographic surgery. Mayo Clin Proc. Feb 1988;63(2):175-83. [Medline].

  17. Ducic Y, Marra DE, Kennard C. Initial Mohs surgery followed by planned surgical resection of massive cutaneous carcinomas of the head and neck. Laryngoscope. Apr 2009;119(4):774-7. [Medline].

  18. Silverman MK, Kopf AW, Gladstein AH, Bart RS, Grin CM, Levenstein MJ. Recurrence rates of treated basal cell carcinomas. Part 4: X-ray therapy. J Dermatol Surg Oncol. Jul 1992;18(7):549-54. [Medline].

  19. Aldara cream 5% (imiquimod) [package insert]. Graceway Pharmaceuticals; 2007.

  20. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. May 2004;50(5):722-33. [Medline].

  21. Sapijaszko MJ. Imiquimod 5% cream (Aldara) in the treatment of basal cell carcinoma. Skin Therapy Lett. Jul-Aug 2005;10(6):2-5. [Medline]. [Full Text].

  22. Micali M, Nasca MR, Musumeci ML. Treatment of an extensive superficial basal cell carcinoma of the face with imiquimod 5% cream. Int J Tissue React. 2005;27(3):111-4. [Medline].

  23. Bilu D, Sauder DN. Imiquimod: modes of action. Br J Dermatol. Nov 2003;149 Suppl 66:5-8. [Medline].

  24. Wuest M, Dummer R, Urosevic M. Induction of the members of Notch pathway in superficial basal cell carcinomas treated with imiquimod. Arch Dermatol Res. Dec 2007;299(10):493-8. [Medline].

  25. Efudex (fluorouracil) [package insert]. Valeant Pharmaceuticals; 2005.

  26. Braathen LR, Szeimies RM, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol. Jan 2007;56(1):125-43. [Medline].

  27. Mosterd K, Thissen MR, Nelemans P, et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. Br J Dermatol. Sep 2008;159(4):864-70. [Medline].

  28. Rhodes LE, de Rie MA, Leifsdottir R, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol. Sep 2007;143(9):1131-6. [Medline].

  29. Rhodes LE, de Rie MA, Leifsdottir R, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol. Sep 2007;143(9):1131-6. [Medline].

  30. [Guideline] Morton CA, McKenna KE, Rhodes LE, et al. Guidelines for topical photodynamic therapy: update. Br J Dermatol. Dec 2008;159(6):1245-66. [Medline].

  31. Brodland DG. Diagnosis of nonmelanoma skin cancer. Clin Dermatol. Nov-Dec 1995;13(6):551-7. [Medline].

  32. Frankel DH, Hanusa BH, Zitelli JA. New primary nonmelanoma skin cancer in patients with a history of squamous cell carcinoma of the skin. Implications and recommendations for follow-up. J Am Acad Dermatol. May 1992;26(5 Pt 1):720-6. [Medline].

  33. Fritsch P. Dermatologie und Venerologie. 2nd ed. Berlin, Germany: Springer; 2004.

  34. Goldman L, Gregory RO, La Plant M. Preliminary investigative studies with PDT in dermatologic and plastic surgery. Lasers Surg Med. 1985;5(5):453-6. [Medline].

  35. Kirkham N. Tumors and cysts of the epidermis. In: Elder D, Elenitas R, Jaworsky C, Johnson B, eds. Lever's Histopathology of the Skin. 8th ed. Philadelphia, Pa: Lippincott-Raven; 1997:719-46.

  36. Lang PG, Maize JC. Basal cell carcinoma. In: Friedman RJ, Rigel, Kopf AW, Harris MN, Baker D, eds. Cancer of the Skin. Philadelphia, Pa: WB Saunders; 1991:35-73.

  37. Lowe L. Histology: basal cell carcinoma. In: Maloney ME, Miller SJ, eds. Cutaneous Oncology. Oxford, England: Blackwell Science; 1998:633-45.

  38. Maloney ME, Miller SJ. Aggressive versus nonaggressive subtypes: basal cell carcinoma. In: Maloney ME, Miller SJ, eds. Cutaneous Oncology. Oxford, England: Blackwell Science; 1998:609-13.

  39. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol. May 1994;30(5 Pt 1):774-8. [Medline].

  40. Miller SJ. Pathogenesis: basal cell carcinoma. In: Maloney ME, Miller SJ, eds. Cutaneous Oncology. Oxford, England: Blackwell Science; 1998:581-5.

  41. Nguyen TH, Ho DQ. Nonmelanoma skin cancer. Curr Treat Options Oncol. Jun 2002;3(3):193-203. [Medline].

  42. Pasca di Magliano M, Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer. Dec 2003;3(12):903-11. [Medline].

  43. Poniecka AW, Alexis JB. An immunohistochemical study of basal cell carcinoma and trichoepithelioma. Am J Dermatopathol. Aug 1999;21(4):332-6. [Medline].

  44. Ponten F, Lundeberg J. Principles of Tumor Biology and Pathogensesis of BCCs and SCCs. In: Bolognia JL, et al, eds. Dermatology. Vol 2. ed. China: Mosby; 2004:1663-76.

  45. Preston DS, Stern RS. Nonmelanoma cancers of the skin. N Engl J Med. Dec 3 1992;327(23):1649-62. [Medline].

  46. Ratner D, Skouge JW. Surgical management of local disease: basal cell carcinoma. In: Maloney ME, Miller SJ, eds. Cutaneous Oncology. Oxford, England: Blackwell Science; 1998:664-71.

  47. Robinson JK. What are adequate treatment and follow-up care for nonmelanoma cutaneous cancer?. Arch Dermatol. Mar 1987;123(3):331-3. [Medline].

  48. Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med. Nov 24 2005;353(21):2262-9. [Medline].

  49. Silverman MK, Kopf AW, Grin CM, Bart RS, Levenstein MJ. Recurrence rates of treated basal cell carcinomas. Part 1: Overview. J Dermatol Surg Oncol. Sep 1991;17(9):713-8. [Medline].

  50. Tope WD, Shaffer JJ. Photodynamic Therapy. In: Bolognia JL, et al, eds. Dermatology. Vol 2. ed. China: Mosby; 2004:2127-40.

  51. Tromovitch TA, Stegeman SJ. Microscopically controlled excision of skin tumors. Arch Dermatol. Aug 1974;110(2):231-2. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Michael L Ramsey, MD, Director, Mohs Surgery Fellowship, Co-Director, Procedural Dermatology Fellowship, Department of Dermatology, Geisinger Medical Center
Michael L Ramsey, MD is a member of the following medical societies: American Academy of Dermatology, American College of Mohs Micrographic Surgery and Cutaneous Oncology, and American Society for Dermatologic Surgery
Disclosure: Nothing to disclose.

Coauthor(s)

Lindsay Dane Sewell, MD, Staff Physician, Department of Dermatology, Geisinger Medical Center
Lindsay Dane Sewell, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

Medical Editor

R Stan Taylor, MD, Professor of Dermatology, University of Texas Southwestern Medical School; Director of Skin Surgery and Oncology Clinic, Department of Dermatology, University of Texas Southwestern Medical Center
R Stan Taylor, MD is a member of the following medical societies: American Academy of Dermatology, American College of Mohs Surgery, American Dermatological Association, American Medical Association, American Society for Dermatologic Surgery, Christian Medical & Dental Society, and Society for Investigative Dermatology
Disclosure: Nothing to disclose.

Pharmacy Editor

David F Butler, MD, Professor of Dermatology, Texas A&M University College of Medicine; Chair, Department of Dermatology, Director, Dermatology Residency Training Program, Scott and White Clinic, Northside Clinic
David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa
Disclosure: Nothing to disclose.

Managing Editor

Edward F Chan, MD, Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania School of Medicine
Edward F Chan, MD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, and Society for Investigative Dermatology
Disclosure: Nothing to disclose.

CME Editor

Catherine M Quirk, MD, Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania
Catherine M Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology
Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.